Latest Conference Articles

Dr. McDermott on Nivolumab Plus Ipilimumab in RCC

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in renal cell carcinoma (RCC).

Immunotherapy Combo Regimens Next Step in Bladder Cancer

Elizabeth Plimack, MD, discusses the impact of the immunotherapy approvals in the first- and second-line setting for bladder cancer and the future of combinations for these patients.

Optimizing Adjuvant Therapy in Renal Cell Carcinoma

Patients with high-risk renal cell carcinoma who harbor early systemic dissemination with very poor survival prognosis may derive some benefit from adjuvant therapy.

Immunotherapy Continues to Shape Future Bladder Cancer Paradigm

Maria De Santis, MD, discusses the findings of KEYNOTE-045 and the future of immunotherapy in the treatment landscape of bladder cancer.

Dr. Capitanio Discusses Adjuvant Therapy for High-Risk Kidney Cancer

Umberto Capitanio, MD, FEBU, department of Urology, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases.

Dr. Powles on the Impact of Immunotherapy in Kidney Cancer

Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer.

Next Steps in Bladder Cancer to Include Combination Immunotherapy

Andrea Necchi, MD, discusses the evolution of bladder cancer therapies, the challenge with the currently available agents, and the next steps and clinical trials being conducted in the field.

Molecular Subtypes Prognostic for OS, DFS in Clear-Cell RCC

Four molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with striking differences seen in overall survival and disease-free survival between each of the groups.

Dr. Junker on Need to Identify Biomarkers to Predict Response to RCC Treatment

Kerstin Junker, MD, associate professor, Department of Urology, Universit

Dr. Mason on the Significance of the PROTECT Study in Prostate Cancer

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in prostate cancer during the 2017 EMUC Congress.

LDH a Predictor for OS in mCRPC Following Radium-223

Log LDH was the strongest predictor for overall survival with radium-223 for men with metastatic castration resistant prostate cancer.

Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC

An extension in overall survival seen with the combination of nivolumab and ipilimumab has completely changed the standard of care for patients with metastatic renal cell carcinoma.

Dr. Volpe Discusses the Management of Localized Kidney Cancer

Alessandro Volpe, MD, University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy, discusses the management of locally advanced kidney cancer.

Pembrolizumab, Atezolizumab New Standards for Bladder Cancer

A wealth of new clinical trial data for immune checkpoint inhibitors has recently been reported for the treatment of patients with metastatic muscle-invasive urothelial carcinoma.

Combining Partial Metastasectomy With Systemic Treatment Beneficial in mRCC

The addition of incomplete metastasectomy to systemic therapy improved median overall survival by 3 months in patients with metastatic renal cell carcinoma.

PI-RADS Offers Prognostic Advantage Over mpMRI Alone for Prostatectomy

Use of the novel prostate imaging reporting and data system enhanced the ability to determine prostate cancer stage versus standard multiparametric MRI alone, offering advantages for deciding the extent of resection needed during an endoscopic radical prostatectomy.

Dr. Necchi on Impact of PD-1 Inhibition in Bladder Cancer

Andrea Necchi, MD, a medical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, discusses the impact of PD-1 inhibition in bladder cancer as well as the promise with combination strategies.

Dr. Markman on Endpoints in Clinical Trials for Ovarian Cancer

Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses endpoints in clinical trials for ovarian cancer.

Dr. Bendell on the Future of Regorafenib for Patients With CRC

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

Comparing Abiraterone and Docetaxel in Prostate Cancer Treatment

Christopher Sweeney, MBBS, physician, Dana-Farber Cancer Institute, compares treatment with abiraterone verus docetaxel in patients with prostate cancer.

EGFR-Positive NSCLC Is Emerging as Model for Precision Medicine

It has been a “renaissance” in the non–small cell lung cancer landscape with the rapid evolution of targeted treatment for patients with EGFR-mutation–positive disease, says Edward S. Kim, MD.

Dr. Garon on Immunotherapy as Salvage Treatment for Advanced Lung Cancer

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

Treating Advanced Non-Driver Lung Adenocarcinoma

The approach to first-line treatment of advanced non-small cell lung cancer (NSCLC) has been evolving rapidly, particularly with respect to patients with lung adenocarcinoma.

MSI-H Experience Delivers Another Exciting Breakthrough in Immuno-Oncology

Immunotherapy is being positioned as an earlier therapeutic option for patients with high levels of microsatellite instability or mismatch repair deficiency, regardless of their tumor location, expert says.

Combinations Required to Further Advance Adoptive T-Cell Therapy

A variety of adoptive T-cell therapy strategies have shown promise in clinical studies with recent FDA approvals granted to CAR-modified T-cell therapies, representing the potential for future combination strategies.

Dr. Finn on the Revolution of CDK4/6 Inhibition in HR+ Breast Cancer

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the significant advances with CDK4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.

PARPs Bring Excitement to Ovarian Treatment

PARP inhibitors offer exciting opportunities to improve outcomes for patients with ovarian cancer and hopefully will be moved to the front-line setting if the evidence warrants it, said Susana M. Campos, MD.

Dr. Eng on Roles of Regorafenib and TAS-102 in CRC Treatment

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ongoing roles of regorafenib (Stivarga) and TAS-102 (Lonsurf) in colorectal cancer (CRC) treatment.

How Reliable Is PD-L1 Expression as a Predictor of Immune Response?

There is a great need—and opportunity—to improve ovarian cancer outcomes by understanding the immune milieu of ovarian cancers and harnessing the power of immunotherapy.

Endometrial Cancer Enters Immunotherapy Age

The tumor-site agnostic FDA approval of the PD-1 inhibitor pembrolizumab (Keytruda) for patients with microsatellite instability-high or mismatch repair deficient solid tumors has helped propel endometrial cancer into the immunotherapy age.